First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.55 USD -1.07% Market Closed
Updated: Apr 19, 2024

Gross Margin
Editas Medicine Inc

0%
Current
0%
Average
62%
Industry
Negative for the last year
0%
Negative average
0%
Worse than average
Worse than industry value

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
0%
=
Gross Profit
0
/
Revenue
78.1m

Gross Margin Across Competitors

Gross Margin Comparison
Editas Medicine Inc Competitors

Country Company Market Cap Gross
Margin
US
Editas Medicine Inc
NASDAQ:EDIT
453.4m USD
0%
US
Abbvie Inc
NYSE:ABBV
290.8B USD
66%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
70%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.4B USD
87%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.8B USD
86%
AU
CSL Ltd
ASX:CSL
131.1B AUD
52%
US
Gilead Sciences Inc
NASDAQ:GILD
82.4B USD
78%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
US
Moderna Inc
NASDAQ:MRNA
39B USD
31%
US
Biogen Inc
NASDAQ:BIIB
27.6B USD
74%
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD
75%
Editas Medicine Inc
NASDAQ:EDIT
Country US
Market Cap 453.4m USD
Gross Margin
0%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 290.8B USD
Gross Margin
66%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 140.7B USD
Gross Margin
70%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 101.4B USD
Gross Margin
87%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 97.8B USD
Gross Margin
86%
CSL Ltd
ASX:CSL
Country AU
Market Cap 131.1B AUD
Gross Margin
52%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 82.4B USD
Gross Margin
78%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Gross Margin
75%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 39B USD
Gross Margin
31%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 27.6B USD
Gross Margin
74%
Horizon Therapeutics PLC
NASDAQ:HZNP
Country IE
Market Cap 26.6B USD
Gross Margin
75%

Profitability Report

View the profitability report to see the full profitability analysis for Editas Medicine Inc.

Full Profitability Report

See Also

Summary
EDIT intrinsic value, competitors valuation, and company profile.
DCF Valuation
EDIT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EDIT stock valuation using valuation multiples.
Wall Street Estimates
EDIT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EDIT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
0%
=
Gross Profit
0
/
Revenue
78.1m
What is the Gross Margin of Editas Medicine Inc?

Based on Editas Medicine Inc's most recent financial statements, the company has Gross Margin of 0%.

ALPHA SPREAD
Join more than 129,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.